AZA-FINANCE
12.11.2022 00:36:35 CET | Business Wire | Press release
Statement from Elizabeth Rossiello, CEO and founder of AZA Finance, on the FTX Chapter 11 Bankruptcy filing:
“I was shocked and disappointed to see that FTX named BTC Africa S.A. and other AZA Finance entities in its Chapter 11 bankruptcy filing today. To be clear: AZA Finance entities are not affected by the FTX bankruptcy, and we are taking steps to correct the erroneous court filings.
AZA Finance is a global payments and foreign exchange fintech. Founded in 2013 as BitPesa, we empower companies worldwide and within Africa to move money, exchange currencies, make payments and settle easily across all major African and G20 currencies (including some digital currencies). AZA Finance is licensed in multiple jurisdictions as a payments provider. We do not hold customer funds and never have. Less than 10% of our transactions across all of our entities are via digital currencies.
Earlier this year, we announced a commercial partnership with FTX Africa to expand web3 in Africa by helping them build regulated, safe and low-cost payments rails, as well as other discussed but not-yet-launched initiatives such as African artist NFT collections.
In doing so, FTX Africa became a customer of AZA Finance, first utilising our stable and efficient infrastructure to pay out to a small number of customers in Africa. However, neither FTX nor any of its associated entities own or control AZA Finance or our entities, including BTC Africa SA. Our entities are not part of the FTX bankruptcy. In its disorganised haste, FTX erroneously listed our entities in their bankruptcy filing.
For additional clarity, our entities that are not part of the FTX bankruptcy include:
- B Transfer Services Limited UK
- Exchange4Free Limited UK
- BTC Africa SA
- BT Payment Services Ghana Limited
- BT Payment Services Nigeria Limited
- BT Payment Services Uganda Limited/B Transfer Services
- BT Payment Services South Africa PTy
- TransferZero
- B For Transfer Egypt
- B Transfer Services Ltd UAE
- BitPesa Kenya Ltd
- BitPesa Senegal Ltd
- BitPesa South Africa
- BitPesa Tanzania Ltd
- BitPesa Uganda Ltd
- BitPesa RDC SARL
- BTPesa Nigeria Limited
- BTSL Limited Tanzania
- Exchange4Free Seychellen
- Exchange4Free Australia Br.
- Exchange4Free Swiss Br.
- Exchange4Free SouthAfrica Br.
- FinFax Company Limited
These entities are not impacted by the FTX bankruptcy in any way. AZA Finance, our entities and our businesses remain independent and healthy.
AZA Finance is and was one of the first Fintech companies to launch from Nairobi, Kenya - and the first foreign currency exchange globally to also trade crypto to mobile money. Volatility is not something that surprises or affects us. We are sad to see a major brand fail, and we urge all fintechs and financial institutions to adhere to global regulation and industry best practices.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005572/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
